Latest filings (excl ownership)
6-K
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
29 Apr 24
424B3
Prospectus supplement
24 Apr 24
EFFECT
Notice of effectiveness
23 Apr 24
POS AM
Prospectus update (post-effective amendment)
18 Apr 24
20-F
2023 FY
Annual report (foreign)
18 Apr 24
6-K
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
18 Apr 24
6-K
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
3 Apr 24
424B5
Prospectus supplement for primary offering
30 Jan 24
6-K
Current report (foreign)
30 Jan 24
6-K/A
Current report (foreign) (amended)
21 Dec 23
6-K
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
20 Dec 23
6-K
Addex Creates Treasury Shares
14 Dec 23
424B3
Prospectus supplement
30 Nov 23
EFFECT
Notice of effectiveness
30 Nov 23
POS AM
Prospectus update (post-effective amendment)
29 Nov 23
6-K
Current report (foreign)
29 Nov 23
6-K
Addex Convenes Extraordinary General Meeting
28 Nov 23
6-K
Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
14 Nov 23
6-K
Current report (foreign)
8 Nov 23
424B3
Prospectus supplement
23 Oct 23
6-K
Addex Completes ADS Ratio Change
20 Oct 23
F-6 POS
Automatic registration for ADRs (post-effective amendment, foreign)
6 Oct 23
6-K
Addex Announces Plan to Implement ADS Ratio Change
6 Oct 23
6-K
Addex mGlu2 NAM Cognition Program Receives €4 Million Grant
20 Sep 23
6-K
Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024
5 Sep 23
6-K
Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain
5 Sep 23
424B3
Prospectus supplement
11 Aug 23
EFFECT
Notice of effectiveness
11 Aug 23
POS AM
Prospectus update (post-effective amendment)
10 Aug 23
6-K
Current report (foreign)
10 Aug 23
6-K
Current report (foreign)
3 Aug 23
6-K
Current report (foreign)
24 Jul 23
6-K
Addex Increases Issued Share Capital to Create Treasury Shares
15 Jun 23
S-8
Registration of securities for employees
8 Jun 23
EFFECT
Notice of effectiveness
5 Jun 23
424B3
Prospectus supplement
2 Jun 23
F-1/A
Registration statement (foreign) (amended)
1 Jun 23
6-K
Addex Shareholders Approve All Resolutions at Annual General Meeting
1 Jun 23
CORRESP
Correspondence with SEC
1 Jun 23
6-K
Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
18 May 23
Latest ownership filings
SC 13D/A
Growth Equity Opportunities Fund IV, LLC
8 Dec 23
SC 13D/A
Dyer Timothy Mark
29 Nov 23
SC 13D/A
Growth Equity Opportunities Fund IV, LLC
10 Apr 23
SC 13D/A
Dyer Timothy Mark
5 Apr 23
SC 13D/A
Dyer Timothy Mark
31 Mar 23
SC 13G/A
ARMISTICE CAPITAL, LLC
16 Feb 23
SC 13G/A
CAXTON CORP
14 Feb 23
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 23
SC 13G/A
GOLDMAN SACHS GROUP INC
8 Feb 23
SC 13G/A
New Leaf Biopharma Opportunities I, L.P.
6 Feb 23
SC 13D/A
Growth Equity Opportunities Fund IV, LLC
28 Nov 22
SC 13D/A
Dyer Timothy Mark
23 Nov 22
SC 13D/A
Dyer Timothy Mark
9 Nov 22
SC 13D/A
Growth Equity Opportunities Fund IV, LLC
23 Aug 22
SC 13D/A
Dyer Timothy Mark
5 Aug 22
SC 13G/A
New Leaf Biopharma Opportunities I, L.P.
18 Feb 22
SC 13G
ARMISTICE CAPITAL, LLC
15 Feb 22
SC 13G
GOLDMAN SACHS GROUP INC
14 Feb 22
SC 13G/A
CREDIT SUISSE AG/
14 Feb 22
SC 13G/A
CAXTON CORP
14 Feb 22
SC 13G/A
New Leaf Biopharma Opportunities I, L.P.
11 Feb 22
SC 13D/A
Growth Equity Opportunities Fund IV, LLC
10 Jan 22
SC 13D/A
Dyer Timothy Mark
8 Sep 21
SC 13G
CAXTON CORP
16 Feb 21
SC 13G
CREDIT SUISSE AG/
12 Feb 21
SC 13G
New Leaf Biopharma Opportunities I, L.P.
10 Feb 21
SC 13D
Growth Equity Opportunities Fund IV, LLC
22 Jan 21
SC 13D
Dyer Timothy Mark
3 Nov 20